Blog

Jun Qi: Our article on EP300/CBP bromodomain inhibition in Group 3 medulloblastoma is now published

Photo taken from Jun Qi/LinkedIn

May 1, 2024, 01:17

Jun Qi: Our article on EP300/CBP bromodomain inhibition in Group 3 medulloblastoma is now published

Jun Qi, Assistant Professor of Medicine at Dana-Farber Cancer Institute, shared a post on LinkedIn:

“It is so exciting to see our collaborative work with Adam Durbin, Ernst Schonbrunn, Martine Roussel, and Brian Abraham to study EP300/CBP bromodomain inhibition in Group 3 medulloblastoma is now published in Nature Communications! It is interesting to see that different type of cancers might rely on EP300/CBP functions very differently. We can use the chemical tool compounds to dissect them out. We are eager to learn more about the pediatric brain tumor and hopefully can find novel therapy for these tough cancers using our chemistry expertise.”

Jun Qi

Additional information
Source: Jun Qi/LinkedIn

Adam Durbin Brian Abraham cancer cancer care Dana-Farber Cancer Institute Ernst Schonbrunn Jun Qi Martine Roussel Nature Communications OncoDaily Oncology patient care

Bernard Fox received SITC lifetime achievement award

Karen Knudsen: Better Together - Partnering to Accelerate Progress against Cancer

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Special Coverage